Thomas Tray - Incyte Chief Finance

INCY Stock  USD 60.58  0.24  0.40%   

Executive

Thomas Tray is Chief Finance of Incyte
Age 47
Address 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
Phone302 498 6700
Webhttps://www.incyte.com

Latest Insider Transactions

2024-12-16Disposed of 650 shares @ 69.31View
2024-12-13Disposed of 650 shares @ 70.64View
2024-09-12Disposed of 572 shares @ 62.94View
2024-06-06Disposed of 1093 shares @ 58.91View

Thomas Tray Latest Insider Activity

Tracking and analyzing the buying and selling activities of Thomas Tray against Incyte stock is an integral part of due diligence when investing in Incyte. Thomas Tray insider activity provides valuable insight into whether Incyte is net buyers or sellers over its current business cycle. Note, Incyte insiders must abide by specific rules, including filing SEC forms every time they buy or sell Incyte'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Incyte Management Efficiency

At this time, Incyte's Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.02 in 2025, whereas Return On Equity is likely to drop 0.01 in 2025. At this time, Incyte's Asset Turnover is fairly stable compared to the past year. Incyte's management efficiency ratios could be used to measure how well Incyte manages its routine affairs as well as how well it operates its assets and liabilities.
Incyte currently holds 37.96 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Incyte has a current ratio of 3.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Incyte's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Hayley SofferIonis Pharmaceuticals
N/A
Kenneth MyszkowskiArrowhead Pharmaceuticals
58
MS MDHarmony Biosciences Holdings
N/A
Eric SwayzeIonis Pharmaceuticals
59
Leigh PetersonUnited Therapeutics
N/A
Malini Moorthyargenx NV ADR
55
Timothy MainesAlnylam Pharmaceuticals
N/A
Laura HansenDenali Therapeutics
N/A
Gregory MDBiomarin Pharmaceutical
N/A
Jeffrey MBAHarmony Biosciences Holdings
53
Evan MBAAlnylam Pharmaceuticals
N/A
Erika ZavodACADIA Pharmaceuticals
N/A
Samantha ProutAmicus Therapeutics
47
Elizabeth ThompsonACADIA Pharmaceuticals
49
Vimal SrivastavaUltragenyx
60
Cristin HubbardBiomarin Pharmaceutical
N/A
MBA JDHarmony Biosciences Holdings
50
Adam TownsendApellis Pharmaceuticals
47
Peter Ulrichtsargenx NV ADR
45
Jeffrey AjerBiomarin Pharmaceutical
62
Humaira SerajuddinBiomarin Pharmaceutical
N/A
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. Incyte Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2094 people. Incyte (INCY) is traded on NASDAQ Exchange in USA. It is located in 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803 and employs 2,617 people. Incyte is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Incyte Leadership Team

Elected by the shareholders, the Incyte's board of directors comprises two types of representatives: Incyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Incyte. The board's role is to monitor Incyte's management team and ensure that shareholders' interests are well served. Incyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Incyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Tray, Chief Finance
Mr MD, Head VP
Pamela Murphy, Vice Communications
Sheila JD, General VP
Patrick Mayes, Vice Research
Paula Swain, Executive Resources
Christine Chiou, Head Relations
Michael Morrissey, Executive Operations
PharmD MBA, Executive America
Vijay MD, Product Affairs
Herve Hoppenot, Chairman, CEO and President and Member of Non-Management Stock Option Committee
Dashyant Dhanak, Executive Vice President Chief Scientific Officer
Steven MD, Executive Officer
Christiana MBA, Executive CFO
Maria JD, Gen VP
MBA MBA, Ex America
Ben Strain, Head Relations
Sheila Denton, Executive Counsel

Incyte Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Incyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Incyte Stock Analysis

When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.